Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | norepinephrine transporter | 0.1136 | 0.5 | 0.5 |
Echinococcus multilocularis | serotonin transporter | 0.1136 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1136 | 0.5 | 0.5 |
Echinococcus granulosus | serotonin transporter | 0.1136 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1136 | 0.5 | 0.5 |
Loa Loa (eye worm) | serotonin transporter b | 0.1136 | 0.5 | 0.5 |
Loa Loa (eye worm) | solute carrier family 6 member 4 | 0.1136 | 0.5 | 0.5 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.1136 | 0.5 | 0.5 |
Schistosoma mansoni | norepinephrine/norepinephrine transporter | 0.1136 | 0.5 | 0.5 |
Treponema pallidum | sodium- and chloride- dependent transporter | 0.1136 | 0.5 | 0.5 |
Onchocerca volvulus | 0.1136 | 0.5 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.1136 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 1.1 mM | Inhibition of bovine brain PKC | ChEMBL. | 17609123 |
Inhibition (functional) | = 39.4 % | Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 5 mg/kg, po after 24 hrs | ChEMBL. | 17609123 |
Inhibition (functional) | = 39.4 % | Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 5 mg/kg, po after 24 hrs | ChEMBL. | 17609123 |
Inhibition (functional) | = 54.5 % | Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 10 mg/kg, po after 24 hrs | ChEMBL. | 17609123 |
Inhibition (functional) | = 54.5 % | Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 10 mg/kg, po after 24 hrs | ChEMBL. | 17609123 |
Inhibition (functional) | = 66.7 % | Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 20 mg/kg, po after 24 hrs | ChEMBL. | 17609123 |
Inhibition (functional) | = 66.7 % | Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 20 mg/kg, po after 24 hrs | ChEMBL. | 17609123 |
Papp (ADMET) | = 7.01 10^-6 cm/s | Permeability from basolateral to apical side of human Caco2 cell membrane | ChEMBL. | 17609123 |
Papp (ADMET) | = 7.01 10^-6 cm/s | Permeability from basolateral to apical side of human Caco2 cell membrane | ChEMBL. | 17609123 |
Papp (ADMET) | = 11.89 10^-6 cm/s | Permeability from apical to basolateral side of human Caco2 cell membrane | ChEMBL. | 17609123 |
Papp (ADMET) | = 11.89 10^-6 cm/s | Permeability from apical to basolateral side of human Caco2 cell membrane | ChEMBL. | 17609123 |
Ratio (ADMET) | = 1.7 | Ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cell membrane | ChEMBL. | 17609123 |
Time (ADMET) | = 118.3 s | Gastrointestinal toxicity in mouse assessed as tail bleeding time at 200 mg/kg, po after 30 mins | ChEMBL. | 17609123 |
Time (ADMET) | = 118.3 s | Gastrointestinal toxicity in mouse assessed as tail bleeding time at 200 mg/kg, po after 30 mins | ChEMBL. | 17609123 |
Time (ADMET) | = 118.5 s | Gastrointestinal toxicity in mouse assessed as tail bleeding time at 200 mg/kg, po after 60 mins | ChEMBL. | 17609123 |
Time (ADMET) | = 118.5 s | Gastrointestinal toxicity in mouse assessed as tail bleeding time at 200 mg/kg, po after 60 mins | ChEMBL. | 17609123 |
Time (ADMET) | = 118.7 s | Gastrointestinal toxicity in mouse assessed as tail bleeding time at 200 mg/kg, po after 90 mins | ChEMBL. | 17609123 |
Time (ADMET) | = 118.7 s | Gastrointestinal toxicity in mouse assessed as tail bleeding time at 200 mg/kg, po after 90 mins | ChEMBL. | 17609123 |
Time (ADMET) | = 118.9 s | Gastrointestinal toxicity in mouse assessed as tail bleeding time at 200 mg/kg, po after 45 mins | ChEMBL. | 17609123 |
Time (ADMET) | = 118.9 s | Gastrointestinal toxicity in mouse assessed as tail bleeding time at 200 mg/kg, po after 45 mins | ChEMBL. | 17609123 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.